Project: Selection and development of a therapeutic antibody against drug-resistant Klebsiella pneumoniae
| Acronym | SPARKLE (Reference Number: 11302) |
| Duration | 01/11/2017 |
| Project Topic | The consortium will develop and perform the preclinical validation of an innovative therapeutic strategy against antibiotic-resistant Klebsiella pneumoniae (ARKP) infections. Klebsiella pneumoniae (KP) is a common hospital-acquired pathogen for which, due to resistance, treatment options are very limited. The therapy is based on a therapeutic monoclonal antibody (mAb) that specifically targets ARKP. Upon completion of the project, the mAb product will be ready for further clinical development. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 7 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Evaxion Biotech | Coordinator | Denmark |
| 2 | MAB Discovery | Partner | Germany |
| 3 | Pepscan Therapeutics BV | Partner | Netherlands |
| 4 | Preclin Biosystems AG | Partner | Switzerland |
| 5 | Karolinska Institute | Partner | Sweden |